Compare Citius Pharmaceuticals Inc (CTXR) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Moody's Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Moody's Corporation trades at $464.23 (market cap $79.44B). The key difference: Moody's Corporation is far larger — about 5832.6× Citius Pharmaceuticals Inc's market cap, and Moody's Corporation pays a 0.9% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Moody's Corporation for 132 Days on average.
| CTXR | MCO | |
|---|---|---|
Market Cap | $13.62M | $79.44B |
Volume | 132,438 | 526,684 |
Sector | Health | Financials |
52-Week High | $1.82 | $539.61 |
52-Week Low | $0.48 | $412.23 |
Typical Hold Time | 17 Days | 132 Days |
Enterprise Value | $3.79M | $85.46B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
MCO trades at $458.69, up 2.01% today, with a bearish technical signal but strong fundamentals including 34.25% net income margin and 80.15% ROE. Recent earnings beats and a consensus price target of $536.40 suggest upside potential. The company announced a minority stake in PhilRatings and a new credit risk model with Allvue, expanding its Asia-Pacific presence and product offerings.
Outlook is positive given consistent earnings growth and strategic expansions, though high valuation multiples and bearish technical indicators near-term pose risks. Analyst consensus is bullish with 56% buy ratings, but investors should monitor debt levels and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
